Health Briefing健康简报
Last updated最近更新 · 2026-09-28 23:38 Asia/Shanghai

Health News Briefing健康新闻简报

China/Asia priority · genetic & immune focus · scannable briefing. Search and filter below; open Organs, People, or Institutions for deep maps.优先中国/亚洲 · 关注遗传与免疫 · 可快速扫读。下方可搜索筛选；器官、人物或机构地图见子页。

33Recent近期 36Archive档案 34Genetic遗传 43Immune免疫 69Individuals人物 34Institutions机构 43China/Asia中国/亚洲

How to use: skim Featured → filter chips or search → open a card source → dive into Organs/People/Institutions maps for spatial context.用法：先看精选 → 用筛选芯片或搜索 → 打开卡片来源 → 需要空间语境时进入器官/人物/机构地图。

Overview — click any tile概览 — 点击色块跳转

FEATURED8 RECENT33 ARCHIVE36 PEOPLE69 GENETIC34 IMMUNE43 CHINA / ASIA43 INSTITUTIONS34

Recent近期动态

33

STTT (Nanjing Medical Univ.): TKTL1–glycolysis–lactate–DC axis drives anti-PD-1 sensitivity in HCC; CQLH nanosystem boosts ICB (preclinical + trial biospecimens)《信号转导与靶向治疗》（南京医科大学）：TKTL1–糖酵解–乳酸–树突状细胞轴驱动肝癌抗PD-1敏感性；CQLH纳米系统可增强免疫检查点阻断（临床前+试验标本）

2026-09-28breakthroughChina/Asia中国/亚洲Immune免疫medium

Cao, Huang, Tang, Xia et al., Signal Transduction and Targeted Therapy (published 28 Sep 2026; DOI 10.1038/s41392-026-02875-2), First Affiliated Hospital of Nanjing Medical University: integrated multi-omics from anti-PD-1-treated HCC patients (perioperative camrelizumab+apatinib trial NCT04297202) identifies TKTL1 as concordantly upregulated in responders. Mechanistically TKTL1 recruits USP9X to stabilize HIF-1α, diverting glucose into glycolysis/lactate rather than the PPP; HIF-1α/CCL4 recruits PD-L1-high dendritic cells, and lactate induces TRIM28 K408 lactylation that stabilizes PD-L1. Authors engineered hepatoma-membrane-coated MnO2 nanosystem CQLH co-delivering a TKTL1 binder (Que) and lactate oxidase, which remodeled the TME and synergized with anti-PD-1 in orthotopic, DEN, and PDTX models—especially TKTL1-high tumors. Flag: biomarker utility still exploratory (modest multi-omics discovery n); CQLH is preclinical proof-of-concept (manufacturing/immunogenicity/regulatory path open); much mechanistic work used DC2.4/in vitro systems.Cao、黄、唐、夏等，《Signal Transduction and Targeted Therapy》（2026年9月28日发表；DOI 10.1038/s41392-026-02875-2），南京医科大学第一附属医院：基于抗PD-1治疗肝癌患者（围手术期卡瑞利珠单抗+阿帕替尼试验NCT04297202）多组学，发现应答者中TKTL1在转录与蛋白层面一致上调。机制上TKTL1招募USP9X稳定HIF-1α，将葡萄糖导向糖酵解/乳酸而非磷酸戊糖途径；HIF-1α/CCL4招募高PD-L1树突状细胞，乳酸诱导TRIM28 K408乳酰化从而稳定PD-L1。作者构建肝癌细胞膜包被的MnO2纳米系统CQLH，共递送TKTL1结合物（Que）与乳酸氧化酶，在原位、DEN及PDTX模型中重塑微环境并与抗PD-1协同——尤其TKTL1高表达肿瘤。需标注：生物标志物效用仍属探索（多组学发现队列有限）；CQLH为临床前概念验证（生产、免疫原性与监管路径未定）；大量机制研究依赖DC2.4/体外体系。

Why it matters: 为何重要：China-led HCC immuno-metabolism map tying a dual prognosis/response biomarker to an actionable nanosystem for PD-1 resistance—high Asia burden disease. Flag preclinical translation gap.中国主导的肝癌免疫代谢图谱，将双重预后/应答生物标志物与可干预纳米策略对接PD-1耐药——高亚洲负担疾病。需标注临床前转化差距。

Signal Transduction and Targeted Therapy ↗ · r-2026-09-tktl1-hcc

Cell (Ruijin): mRNA LNP ABO2203 encodes CD19 T-cell engager — FIH B-cell depletion and platelet recovery in refractory ITP (n=3)《Cell》（瑞金）：mRNA脂质纳米粒ABO2203编码CD19 T细胞衔接器——难治性ITP首次人体实现B细胞清除与血小板恢复（n=3）

2026-09-28breakthroughChina/Asia中国/亚洲Immune免疫medium

Wang, Hu, Yang et al., Cell (Ruijin Hospital / Shanghai Jiao Tong University School of Medicine; DOI 10.1016/j.cell.2026.08.039; Cell article S0092-8674(26)01012-3): ABO2203 is an LNP-formulated mRNA encoding a CD19-targeting T-cell engager. In a first-in-human concept study of three patients with refractory secondary immune thrombocytopenia, the therapy achieved rapid and complete peripheral B-cell depletion with sustained marrow depletion, durable platelet recovery and reduced disease activity through 6 months of follow-up. Adverse events were grade 1–2 only; no cytokine release syndrome reported. B-cell reconstitution favored transitional/naive phenotypes. Flag: n=3 proof-of-concept—durability, broader ITP populations, and long-term safety need larger trials. China media (Shangguan/Xinmin via Sina, 28 Sep 2026) highlighted the FIH mRNA-TCE path alongside Ruijin’s concurrent Cell pancreatic Selenop paper (already covered).Wang、胡琼依、杨程德等，《Cell》（上海交通大学医学院附属瑞金医院；DOI 10.1016/j.cell.2026.08.039；文章号S0092-8674(26)01012-3）：ABO2203为脂质纳米粒递送的编码CD19靶向T细胞衔接器的mRNA药物。在3例难治性继发性免疫性血小板减少症患者的首次人体概念验证中，实现外周血B细胞快速完全清除并伴骨髓持续清除，血小板持久恢复，随访6个月疾病活动改善。不良事件为1–2级，未见细胞因子释放综合征；B细胞重建以过渡性/初始表型为主。需标注：n=3概念验证——持久性、更广ITP人群与长期安全性有待更大规模试验。2026年9月28日上观/新民晚报（新浪转载）在瑞金连续两篇《Cell》报道中突出该mRNA-TCE路径（胰腺癌Selenop论文已收录）。

Why it matters: 为何重要：China-led first-in-human mRNA-encoded T-cell engager for autoimmune B-cell depletion—off-the-shelf alternative to ex vivo cell therapy. Confidence limited by tiny FIH sample.中国主导的mRNA编码T细胞衔接器首次人体用于自身免疫B细胞清除——相对体外细胞治疗更具“现货”潜力。置信度受极小样本量限制。

Institutions: 机构：Ruijin瑞金 · SJTUSM交大医学院

Cell ↗ · r-2026-09-abo2203

Cell Research (Xiamen): blocking magnesium-sensitive RNASET2 dsRNA clearance boosts cancer immunotherapy (preclinical)《Cell Research》（厦门大学）：抑制镁敏感RNASET2双链RNA清除机制可增强肿瘤免疫治疗（临床前）

2026-09-28breakthroughChina/Asia中国/亚洲Genetic遗传Immune免疫medium

Zhang et al., Cell Research Letter (published 28 Sep 2026; DOI 10.1038/s41422-026-01301-0), State Key Laboratory for Cellular Stress Biology, Xiamen University: RNASET2, a ribonuclease that clears mitochondrial double-stranded RNA, dampens innate immune sensing; human RNASET2 deficiency causes childhood cystic leukoencephalopathy with systemic inflammation. Authors report that inhibiting this magnesium-sensitive dsRNA-clearance machinery elevates interferon-stimulated programs and boosts antitumor immunity in preclinical models, with magnesium modulating RNASET2 activity. Mechanistic/preclinical letter—not a clinical trial; therapeutic translation and safety (neuroinflammatory risk from RNASET2 loss) remain open.Zhang等，《Cell Research》快报（2026年9月28日发表；DOI 10.1038/s41422-026-01301-0），厦门大学细胞应激生物学国家重点实验室：RNASET2作为清除线粒体双链RNA的核糖核酸酶可抑制固有免疫感知；人类RNASET2缺陷导致儿童囊性脑白质病并伴全身炎症。作者报告抑制这一镁敏感的dsRNA清除机制可上调干扰素刺激基因表达并在临床前模型中增强抗肿瘤免疫，镁可调节RNASET2活性。属机制/临床前快报——非临床试验；治疗转化及RNASET2缺失相关神经炎症风险仍待明确。

Why it matters: 为何重要：China-led innate-immunity lever linking a Mendelian RNASET2 deficiency pathway to cancer immunotherapy potentiation. Flag: letter-level preclinical evidence only.中国主导的固有免疫杠杆，将孟德尔RNASET2缺陷通路与肿瘤免疫增效相连。需标注：目前仅为快报级临床前证据。

Cell Research ↗ · r-2026-09-rnaset2

IMS 2026: FUCASO (eque-cel) China RWS — 95.9% ORR, 77.2% CR/sCR in 281 heavily pretreated myeloma patientsIMS 2026：福可苏（eque-cel）中国真实世界研究——281例重度预处理骨髓瘤95.9% ORR、77.2% CR/sCR

2026-09-27breakthroughChina/Asia中国/亚洲Immune免疫medium

IASO Bio / Peking University People's Hospital oral at IMS 2026 (OA-09; PR Newswire 26–27 Sep 2026): multicenter China real-world study of commercial fully human BCMA CAR-T FUCASO (equecabtagene autoleucel) since June 2023 launch. n=281 plasma-cell neoplasm patients (median 4 prior lines; 82.4% any high-risk cytogenetics; 47% extramedullary disease). Among 267 efficacy-evaluable: ORR 95.9%, CR/sCR 77.2% (sCR 42.7%), MRD-negativity 94.1%; median follow-up 10.97 months, median PFS/OS not reached (12-mo PFS 71.5%, OS 87.8%). Any-grade CRS 88.2% (grade ≥3 3.8%); ICANS 6.8%; no parkinsonism. Benefit broadly consistent in age >70, prior anti-CD38, and high-risk cytogenetic subgroups. Source is company/conference abstract—not a peer-reviewed journal article; observational RWS without randomized control.IASO/北京大学人民医院于2026年IMS口头报告（OA-09；PR Newswire 2026年9月26–27日）：福可苏（equecabtagene autoleucel，全人源BCMA CAR-T）自2023年6月上市以来的中国多中心真实世界研究。共281例浆细胞肿瘤（中位4线；82.4%存在高危细胞遗传学；47%有髓外病变）。267例疗效可评估：ORR 95.9%，CR/sCR 77.2%（sCR 42.7%），MRD阴性率94.1%；中位随访10.97个月，中位PFS/OS未达到（12个月PFS 71.5%、OS 87.8%）。任何级别CRS 88.2%（≥3级3.8%）；ICANS 6.8%；未见帕金森样表现。>70岁、既往抗CD38及高危细胞遗传学亚组获益大体一致。来源为公司/会议摘要——非同行评议期刊；属无随机对照的观察性真实世界研究。

Why it matters: 为何重要：Largest China commercial BCMA CAR-T real-world readout validating registration-trial depth in higher-risk routine practice. Flag: sponsor/meeting disclosure, observational design, PFS/OS still immature.迄今最大规模中国商业化BCMA CAR-T真实世界读出，在更高危日常诊疗人群中印证注册试验深度缓解。需标注：申办/会议披露、观察性设计，PFS/OS仍不成熟。

Institutions: 机构：PKU Health北大医学部

IASO Bio / IMS 2026 (OA-09) ↗ · r-2026-09-fucaso-rws

CTX310 in vivo CRISPR (ANGPTL3): ~50% LDL and TG cuts hold at 1 year in Phase 1 (NEJM / ESC 2026)CTX310体内CRISPR（ANGPTL3）：一期试验一年后LDL与甘油三酯降幅仍约50%（NEJM/ESC 2026）

2026-09-27breakthroughGenetic遗传medium

Cleveland Clinic / CRISPR Therapeutics Phase 1a (n=15; ScienceDaily 27 Sep 2026; simultaneous NEJM research letter DOI 10.1056/NEJMc2609825; ESC Congress 2026): single IV infusion of CTX310, an LNP CRISPR-Cas9 editor that knocks down hepatic ANGPTL3, produced durable lipid lowering. At the highest dose, mean LDL fell 52.5% and triglycerides 47.8% from baseline at 12 months; no treatment-related serious adverse events reported in the one-year window. Trial funded by CRISPR Therapeutics; investigators’ institution received research funding. Program advancing to Phase 1b; FDA-style 15-year gene-editing follow-up planned. Early, small n—efficacy in broader populations unproven.克利夫兰诊所/CRISPR Therapeutics一期a研究（n=15；ScienceDaily 2026年9月27日；同期《新英格兰医学杂志》研究快报 DOI 10.1056/NEJMc2609825；ESC 2026）：单次静脉输注LNP递送的CRISPR-Cas9编辑器CTX310，敲低肝脏ANGPTL3后血脂降幅在一年随访中仍持续。最高剂量组12个月时LDL平均降52.5%、甘油三酯降47.8%；一年内未见与治疗相关的严重不良事件。试验由CRISPR Therapeutics资助；研究者所在机构获其研究经费。项目推进至一期b；拟按基因编辑要求做最长15年随访。样本小、仍属早期——更广人群疗效未证实。

Why it matters: 为何重要：First one-year durability readout for in vivo CRISPR lipid editing via ANGPTL3—benchmark for hepatic gene-editing CV programs. Flag small n, sponsor funding, and long-term insertional/off-target uncertainty.首次公布经ANGPTL3的体内CRISPR降脂一年持久性数据，可作为肝脏基因编辑心血管管线标杆。需标注小样本、申办方资助及长期插入/脱靶不确定性。

Cleveland Clinic / NEJM (via ScienceDaily) ↗ · r-2026-09-ctx310

IASO206 in vivo BCMA CAR-T: 90% ORR without lymphodepletion in Chinese FIH myeloma study (IMS LBA)IASO206体内BCMA CAR-T：中国FIH骨髓瘤研究无清淋预处理获90% ORR（IMS晚破口）

2026-09-26breakthroughChina/Asia中国/亚洲Genetic遗传Immune免疫medium

At IMS 2026 (late-breaking oral LBA-11; data cutoff 26 Sep 2026), IASO Bio and CAMS Institute of Hematology presented FIH Phase 1 of IASO206: a single IV lentiviral in vivo BCMA CAR-T given without apheresis or lymphodepleting chemo. In 10 R/R MM patients (median 3 prior lines; 90% high-risk / 70% ultra-high-risk cytogenetics), ORR and MRD-negativity were each 90% (100%/100% in high-dose cohort); no DLT, ICANS, or treatment-related deaths; CRS mostly grade 1–2. Source is company/IMS abstract—not a peer-reviewed journal article; n=10 and follow-up still limited.2026年IMS年会晚破口头报告（LBA-11；数据截止2026年9月26日），信达生物系IASO与中国医学科学院血液病医院报告IASO206一期FIH：单次静脉慢病毒体内BCMA CAR-T，无需单采与清淋预处理。10例R/R MM（中位3线；90%高危/70%超高危细胞遗传学）ORR与MRD阴性率均为90%（高剂量组均100%）；无DLT、ICANS或治疗相关死亡；CRS多为1–2级。来源为公司/会议摘要——非同行评议期刊全文；n=10且随访仍有限。

Why it matters: 为何重要：In vivo CAR-T that skips manufacturing wait and lymphodepletion could reshape myeloma access in Asia if durability and larger trials confirm early signals. Flag: meeting/company data only.若持久性与更大规模试验证实早期信号，免制造等待与清淋的体内CAR-T或将重塑亚洲骨髓瘤可及性。需标注：目前仅为会议/公司数据。

Institutions: 机构：CAMS / PUMC医科院/协和医学院

IASO Bio / IMS 2026 (LBA-11) ↗ · r-2026-09-iaso206

Show 27 more recent items展开其余 {len(recent_rest)} 条近期

Nature Medicine: CRISPR CD33-deleted donor HCT (trem-cel) engrafts in high-risk AML/MDS; shields gemtuzumab maintenance (n=30)《自然·医学》：CRISPR敲除CD33的供者造血移植（trem-cel）在高危AML/MDS中成功植入并庇护吉妥珠单抗维持（n=30）

2026-09-25breakthroughGenetic遗传Immune免疫

DiPersio et al., Nature Medicine (ScienceDaily/WashU Medicine 25 Sep 2026; DOI 10.1038/s41591-026-04362-1): multicenter phase 1/2 trial (Siteman + 14 U.S./Canada sites; n=30 adults with high-relapse-risk AML/MDS) transplanted CRISPR-Cas9 CD33-deleted allogeneic HSCs (tremtelectogene empogeditemcel / trem-cel, Vor Biopharma-funded). All 30 engrafted by day 28; platelet recovery averaged day 16—similar to standard HCT. Nineteen received post-transplant gemtuzumab ozogamicin dose escalation and maintained blood counts, suggesting edited grafts were shielded from CD33-directed myelosuppression. Seven deaths (4 disease progression, 3 transplant complications including kidney failure, liver toxicity, sepsis). AE profile broadly resembled conventional transplant (cytopenias, infection, GVHD). Strategy aims to enable safer CD33-targeted immunotherapy/CAR-T after transplant; companion case report (JCO Precis Oncol 2025) described durable remission after trem-cel + donor-derived anti-CD33 CAR-T. Early, sponsor-funded—not yet a standard-of-care claim.DiPersio等，《自然·医学》（ScienceDaily/WashU Medicine 2026年9月25日；DOI 10.1038/s41591-026-04362-1）：多中心1/2期试验（Siteman及美加共15家中心；n=30高复发风险AML/MDS成人）移植经CRISPR-Cas9敲除CD33的异基因造血干细胞（tremtelectogene empogeditemcel/trem-cel，Vor Biopharma资助）。30例均在第28天前植入；血小板恢复平均第16天——与标准移植相近。19例接受移植后吉妥珠单抗（gemtuzumab ozogamicin）剂量爬坡并维持血细胞计数，提示编辑移植物对CD33靶向骨髓抑制具庇护作用。7例死亡（4例疾病进展，3例移植相关含肾衰、肝毒性、脓毒症）。不良事件谱大体同常规移植（血细胞减少、感染、GVHD）。策略旨在移植后更安全地使用CD33靶向免疫/CAR-T；配套病例（JCO Precis Oncol 2025）报告trem-cel联合供者来源抗CD33 CAR-T后持久缓解。属早期、申办方资助研究——尚非标准治疗主张。

Why it matters: 为何重要：Gene-edits the graft so CD33-directed drugs/CAR-T can hit residual AML/MDS without destroying healthy hematopoiesis—key bottleneck for myeloid immunotherapy. Flag small n, sponsor funding, transplant mortality, and that CAR-T combination evidence is still mostly case-level.编辑移植物使CD33靶向药物/CAR-T可打击残留AML/MDS而不摧毁健康造血——髓系免疫治疗关键瓶颈。需标注小样本、申办方资助、移植相关死亡，以及CAR-T联合证据仍多为病例级。

Nature Medicine (via WashU / ScienceDaily) ↗ · r-2026-09-tremcel

RD140 dual BCMA/GPRC5D FasT CAR-T: 88.9% ORR, no ICANS in Chinese FIH (IMS PA-200)RD140双靶BCMA/GPRC5D FasT CAR-T：中国FIH获88.9% ORR且无ICANS（IMS PA-200）

2026-09-25breakthroughChina/Asia中国/亚洲Genetic遗传Immune免疫medium

IMS 2026 poster discussion (PA-200; cutoff 6 May 2026): Peking University People's Hospital / IASO Bio FIH Phase 1 of fully human BCMA/GPRC5D dual-targeted FasT CAR-T RD140 (NCT06655519) in 9 heavily pretreated R/R MM or PCL patients (all triple-class exposed; 6 high-risk cytogenetics). ORR 88.9% (100% at higher dose DL2), MRD-negativity 88.9% at 10^-5; CRS mostly grade 1–2 (1 grade 3); no neurotoxicity/ICANS. FasT platform claims 3–4 day manufacture. Company/meeting disclosure; small n, median follow-up ~6 months.2026年IMS壁报讨论（PA-200；截止2026年5月6日）：北京大学人民医院/IASO报告全人源BCMA/GPRC5D双靶FasT CAR-T RD140一期FIH（NCT06655519），9例重度预处理R/R MM或浆细胞白血病（均三药暴露；6例高危细胞遗传学）。ORR 88.9%（较高剂量DL2为100%），10^-5 MRD阴性率88.9%；CRS多为1–2级（1例3级）；无神经毒性/ICANS。FasT平台宣称3–4天制备。属公司/会议披露；样本量小，中位随访约6个月。

Why it matters: 为何重要：Dual-antigen CAR-T plus rapid manufacture targets antigen escape and vein-to-vein delay—key for high-burden Asia myeloma care. Still early IIT evidence.双抗原CAR-T叠加快速制备针对抗原逃逸与静脉到静脉延迟——对亚洲高负担骨髓瘤救治关键。仍属早期IIT证据。

Institutions: 机构：PKU Health北大医学部 · CAMS / PUMC医科院/协和医学院

IASO Bio / IMS 2026 (PA-200) ↗ · r-2026-09-rd140

Nature Medicine: does expanding China’s clinical-trial capacity improve healthcare access?《Nature Medicine》：中国临床试验产能扩张是否改善医疗可及？

2026-09-25public-healthChina/Asia中国/亚洲

Nature Medicine Comment (25 Sep 2026) notes China’s rapid decade-long trial expansion has been concentrated in top-tier institutions and needs careful management to improve equitable patient access to biomedical innovation.《Nature Medicine》评论（2026年9月25日）指出中国近十年试验产能扩张集中于顶尖机构，需审慎管理以改善患者公平获得生物医药创新的机会。

Why it matters: 为何重要：Capacity ≠ equity; relevant for how gene/cell therapies reach patients beyond elite hospitals.产能≠公平；关系到基因/细胞疗法如何惠及顶尖医院之外的患者。

Institutions: 机构：Zhongshan (Fudan)复旦中山 · PUMCH协和

Nature Medicine ↗ · r-2026-09-trial-access

NEJM: etuvetidigene autotemcel gene therapy for Wiskott–Aldrich — 96% survival at 5 years in 27 patients (median 5.7 y follow-up)《NEJM》：etuvetidigene autotemcel基因治疗Wiskott–Aldrich综合征——27例患者5年生存率96%（中位随访5.7年）

2026-09-24breakthroughGenetic遗传Immune免疫

Ferrua, Aiuti et al., New England Journal of Medicine (reported 24 Sep 2026 via Vita-Salute San Raffaele / SR-Tiget): integrated outcomes of 27 patients treated with etuvetidigene autotemcel (etu-cel), an autologous lentiviral WAS-gene HSC therapy for Wiskott–Aldrich syndrome. Corrected cells engrafted stably with restored WASP expression; severe infections and moderate-to-severe bleeding fell markedly. Survival 96% at 1 and 5 years; median follow-up 5.7 years (some >13 years). By last visit all had stopped immunoglobulin replacement; after 3 years none remained in protective environments, ~80% attended school, ~half participated in sport. No gene-therapy–attributed adverse events reported in the institute summary. Product previously authorized in the US (Dec 2025) and EU (Jan 2026). Flag: details summarized from institutional NEJM announcement pending full-text cross-check of exact numerical secondary endpoints.Ferrua、Aiuti等，《新英格兰医学杂志》（2026年9月24日经圣拉斐尔生命健康大学/SR-Tiget通报）：整合27例接受etuvetidigene autotemcel（etu-cel，自体慢病毒WAS基因造血干细胞疗法）治疗Wiskott–Aldrich综合征的结果。校正细胞稳定植入并恢复WASP表达；严重感染与中重度出血显著减少。1年及5年生存率均为96%；中位随访5.7年（部分超过13年）。末次随访时全部停用免疫球蛋白替代；治疗后3年无人仍需保护性隔离环境，约80%可上学，约半数可参加运动。机构摘要称未见归因于基因治疗的不良事件。该产品此前已于2025年12月获美国、2026年1月获欧盟上市许可。需标注：细节依据机构对NEJM论文的通报，精确次要终点数值仍待全文交叉核对。

Why it matters: 为何重要：Landmark long-term genetic/immune gene-therapy readout for a classic primary immunodeficiency—durable clinical benefit after a single infusion.经典原发性免疫缺陷的里程碑式长期基因治疗读出——单次输注后可获得持久临床获益。

NEJM / San Raffaele-Telethon ↗ · r-2026-09-was-etucel

NEJM: anito-cel D-domain BCMA CAR-T — 100% ORR, ~80% CR in Phase 1 RR multiple myeloma (n=38)《新英格兰医学杂志》：anito-cel（D结构域BCMA CAR-T）一期难治复发骨髓瘤100%总缓解、约80%完全缓解（n=38）

2026-09-24breakthroughImmune免疫

Frigault et al., NEJM (EurekAlert / Mass General Brigham & UChicago Medicine, 24 Sep 2026; DOI 10.1056/NEJMoa2603527): Phase 1 of anitocabtagene autoleucel (anito-cel), a BCMA CAR-T with a synthetic D-domain binder (Kite/Gilead development), in relapsed/refractory multiple myeloma. All 38 treated patients responded; nearly 80% achieved complete response. More than half remained progression-free at two years; estimated overall survival 65% at three years. Investigators report serious immune/neurologic toxicities were uncommon and no delayed neurological complications in this cohort—contrasting with rare but serious neurotoxicity reported for some other BCMA CAR-Ts. Authors hypothesize the D-domain binder may limit excessive immune activation. Phase 2/3 trials ongoing. Phase 1, no randomized control; author COIs in the paper; larger trials required before practice-changing claims.Frigault等，《新英格兰医学杂志》（EurekAlert/Mass General Brigham与芝加哥大学医学中心，2026年9月24日；DOI 10.1056/NEJMoa2603527）：合成D结构域结合域的BCMA CAR-T anitocabtagene autoleucel（anito-cel，Kite/Gilead开发）一期难治/复发多发性骨髓瘤结果。38例接受治疗者全部缓解；近80%达完全缓解。逾半数两年时仍无进展；三年总生存估计约65%。研究者称本队列严重免疫/神经毒性少见、未见迟发性神经并发症——相对部分其他BCMA CAR-T已报告的罕见但严重神经毒性。作者推测D结构域结合域或可限制过度免疫激活。二/三期试验进行中。属一期、无随机对照；论文披露作者利益冲突；改变实践前仍需更大规模试验。

Why it matters: 为何重要：Adds a differentiated BCMA CAR-T binder with early signals of deep durability and a reassuring neurotoxicity profile in RRMM. Flag Phase 1 size, lack of control arm, and sponsor/academic COIs pending Phase 2/3 confirmation.为难治复发骨髓瘤增加一种差异化BCMA CAR-T结合域，早期显示深度持久缓解与较安心的神经毒性信号。需标注一期样本量、无对照臂，以及申办/学术利益冲突，待二/三期证实。

NEJM (via Mass General Brigham / EurekAlert) ↗ · r-2026-09-anito-cel

Cell Stem Cell: phagocytosis-shielded BaEVRLess vectors enable in vivo HSC gene transfer for sickle cell (preclinical)《Cell Stem Cell》：吞噬屏蔽BaEVRLess载体实现体内造血干细胞基因转移治疗镰状细胞病（临床前）

2026-09-24breakthroughGenetic遗传medium

Klatt et al., Cell Stem Cell (online 24 Sep 2026, open access): systemic delivery of CD47-shielded lentiviral/alpha-retroviral vectors pseudotyped with BaEVRLess into mobilized humanized mice achieved up to ~8.8% gene marking in hCD45+ cells, enrichable by chemoselection to ~70% hCD45+ / ~54% HSCs with polyclonal reconstitution. For SCD, erythroid-selective miRNA-embedded shRNAs against BCL11A and ZNF410 induced fetal globin to therapeutically relevant levels (~61.5% of beta-like globins in differentiated erythroid cells). Entirely preclinical mouse data—no human dosing yet.Klatt等，《Cell Stem Cell》（2026年9月24日在线，开放获取）：向动员后人源化小鼠全身递送CD47吞噬屏蔽、BaEVRLess假型慢病毒/α逆转录病毒载体后，hCD45+基因标记最高约8.8%，经化疗筛选可富集至约70% hCD45+/约54% HSC，并呈多克隆重建。针对镰状细胞病，红细胞系选择性miRNA嵌入式shRNA下调BCL11A与ZNF410，诱导胎儿血红蛋白达治疗相关水平（分化红细胞中约占β样珠蛋白61.5%）。全为临床前小鼠数据——尚无人用剂量。

Why it matters: 为何重要：Points toward conditioning-light in vivo HSC gene therapy that could widen SCD access vs ex vivo platforms. Flag mouse-only, chemoselection toxicity, and insertional-risk unknowns before any clinical claim.指向可减轻清髓负担的体内HSC基因治疗路径，或比体外平台更易扩展可及性。需标注仅小鼠、筛选毒性与插入风险，临床外推尚早。

Cell Stem Cell ↗ · r-2026-09-baevr-hsc

Cell: Ruijin/SJTU — tumor-border macrophages transfer Selenop to shield pancreatic cancer from ferroptosis《Cell》：瑞金/交大团队发现瘤周巨噬细胞转运Selenop保护胰腺癌免受铁死亡

2026-09-24breakthroughChina/Asia中国/亚洲Immune免疫medium

A Cell paper (online ~24 Sep 2026) from Ruijin Hospital and Shanghai Jiao Tong University School of Medicine reports that resident tissue macrophages at the pancreatic ductal adenocarcinoma border transfer the selenium transporter protein Selenop to tumor cells. Uptake via LRP8-dependent endocytosis raises selenium availability, limits lipid peroxidation, and helps shield invasive epithelial–mesenchymal transition–high cancer cells from ferroptosis. Evidence draws on single-cell profiling, lineage tracing, and selenium tracing. Mechanistic oncology study—not a therapeutic trial.《Cell》（约2026年9月24日在线）瑞金医院与上海交通大学医学院研究：胰腺导管腺癌边界处驻留组织巨噬细胞向肿瘤细胞转运硒转运蛋白Selenop；经LRP8依赖内吞提高硒可利用度、限制脂质过氧化，使高上皮–间质转化肿瘤细胞更耐受铁死亡。证据包括单细胞图谱、谱系示踪与硒示踪。属机制性肿瘤学研究——非治疗性临床试验。

Why it matters: 为何重要：Links innate immune niche biology to ferroptosis resistance in a China-led PDAC study—potential target space for immune–redox combination strategies if validated therapeutically.将固有免疫微环境与铁死亡抵抗联系起来的中国主导PDAC研究——若获治疗验证，或指向免疫–氧化还原联合策略的靶点空间。

Institutions: 机构：Ruijin瑞金 · SJTUSM交大医学院

Cell ↗ · r-2026-09-cell-selenop

PLOS Medicine: intermediary-facilitated PPM in Viet Nam boosts TB notifications at scale《PLOS Medicine》：越南中介促进公私合作显著提升结核病报病

2026-09-23public-healthChina/Asia中国/亚洲Immune免疫

PLOS Medicine (23 Sep 2026) quasi-experimental evaluation: intermediary-facilitated public–private mix for TB in Viet Nam associated with significant, dose-responsive increases in PPM and TB notifications at provincial/national levels; cost roughly US$166–458 per additional notification.《PLOS Medicine》（2026年9月23日）准实验评估：越南中介促进的结核病公私合作与省/国家级公私合作及结核报病显著、剂量反应式上升相关；每额外报病成本约166–458美元。

Why it matters: 为何重要：Asia bears much of global TB burden; scalable PPM models matter amid constrained global health financing.亚洲承载全球大部分结核负担；在全球卫生筹资趋紧背景下，可扩展公私合作模式尤为重要。

PLOS Medicine ↗ · r-2026-09-vietnam-tb

Nature Medicine: China-led EAGLE AI detects esophageal cancer/HGIN on routine noncontrast chest CT across 80k+ patients《自然·医学》：中国主导EAGLE AI在常规胸部平扫CT上筛查食管癌/高级别上皮内瘤变（验证超8万人）

2026-09-22breakthroughChina/Asia中国/亚洲

Multicenter Nature Medicine paper (published 22 Sep 2026; ChiCTR2300074806): EAGLE, trained at SYSUCC and Sichuan Cancer Hospital (n=6,813) and validated across 12 centers in China/Czech Republic/Australia (opportunistic + population settings totaling >80,000 patients), detects esophageal cancer and high-grade intraepithelial neoplasia from noncontrast chest CT—a task long considered impractical. External opportunistic cohorts (8 centers, n=11,466) reported 98.5% specificity with ~90% cancer sensitivity and 52.5% for precancerous lesions; calibrated EAGLE-Plus cut false positives ~73% in real-world cohorts; prospective hospital deployment (n=17,446) PPV 42.2%. Several Alibaba DAMO/Hupan Lab authors hold company stock. Still AI-assisted triage—not a replacement for endoscopy; precancer sensitivity and endoscopy-triage evidence partly simulation/early prospective.《自然·医学》多中心研究（2026年9月22日发表；ChiCTR2300074806）：EAGLE在中山大学肿瘤防治中心与四川省肿瘤医院训练（n=6,813），并在中国/捷克/澳大利亚共12家中心、涵盖机会性与人群筛查场景的超8万例患者中验证，可从常规胸部平扫CT识别食管癌与高级别上皮内瘤变——既往被认为几乎不可行。外部机会性队列（8中心，n=11,466）特异度约98.5%，癌症灵敏度约90%、癌前病变约52.5%；校准后的EAGLE-Plus在真实世界队列中假阳性约降73%；前瞻性医院部署（n=17,446）阳性预测值42.2%。部分阿里达摩院/壶畔实验室作者持有公司股票。仍属AI辅助分流，不能替代内镜；癌前灵敏度与内镜分诊证据部分来自模拟/早期前瞻。

Why it matters: 为何重要：High China relevance: turns ubiquitous chest CT/LDCT into a scalable esophageal early-detection adjunct and possible endoscopy triage layer. Flag Alibaba affiliations/stock and that HGIN sensitivity and triage gains need larger mature prospective confirmation.对中国高度相关：把已广泛开展的胸部CT/低剂量CT变成可扩展的食管早诊辅助，并可能作为内镜前风险分层。需标注阿里相关利益，以及HGIN灵敏度与分诊获益仍待更成熟前瞻证实。

Nature Medicine ↗ · r-2026-09-eagle-ec

X-Men’s Tyler Mane: male breast cancer battle and BRCA2 mutation; urges earlier genetic testing《X战警》泰勒·梅恩：男性乳腺癌与BRCA2突变；呼吁更早基因检测

2026-09-22individualGenetic遗传

In a Us Weekly exclusive (interview dated 16 Sep; published 22 Sep 2026), Canadian actor Tyler Mane (Sabretooth) described completing four rounds of chemotherapy for rare male breast cancer, a subsequent leg blood clot managed with anticoagulants, and ongoing radiation. After diagnosis he learned he carries a BRCA2 mutation that raises cancer risk; he said earlier genetic testing might have prompted faster evaluation of the lump and possibly avoided chemo/radiation. He stressed men are often diagnosed later because male breast cancer is under-discussed. Personal disclosure—not a clinical study.《Us Weekly》独家（采访9月16日；2026年9月22日刊发）：加拿大演员泰勒·梅恩（剑齿虎）讲述因罕见男性乳腺癌完成四轮化疗、随后出现腿部血栓并以抗凝处理，以及正在进行放疗。确诊后基因检测发现BRCA2突变致癌风险升高；他表示若更早检测或会更快就医评估肿块，或许避免化疗/放疗。他强调男性乳腺癌讨论不足常导致较晚诊断。属个人披露——非临床研究。

Why it matters: 为何重要：High-visibility male BRCA2 / breast-cancer story reinforces hereditary-cancer testing and awareness beyond typical female-focused narratives.高关注度的男性BRCA2/乳腺癌故事，强化遗传性癌症检测意识，并突破以女性为主的常见叙事。

Us Weekly ↗ · r-2026-09-mane-brca2

City of Hope meCAR T: plug-and-play adaptors let CAR-T cells be retargeted after infusion (Cancer Immunol Res)希望之城meCAR T：插拔式接头可在输注后重定向CAR-T（Cancer Immunol Res）

2026-09-21breakthroughGenetic遗传Immune免疫medium

City of Hope reported (EurekAlert 21 Sep 2026; paper in Cancer Immunology Research) a preclinical meditope-enabled CAR (meCAR) platform: engineered T cells dock a small molecule (meP) so clinicians can add tracking, expansion, or new antigen-recognition adaptors after infusion—aiming to keep pace with antigen escape in solid tumors and AML. Two Phase I trials are being developed; no human efficacy data yet. Authors disclose equity/royalty ties to Meditope Biosciences for related technology.希望之城（EurekAlert 2026年9月21日；《Cancer Immunology Research》论文）报告临床前meditope启用CAR（meCAR）平台：工程化T细胞可对接小分子meP，从而在输注后添加示踪、扩增或新抗原识别接头，以应对实体瘤与AML中的抗原逃逸。团队正筹备两项一期试验；尚无人体疗效数据。作者披露与Meditope Biosciences相关技术的股权/特许权利益。

Why it matters: 为何重要：Addresses a core limit of hardwired CAR-T—post-infusion inflexibility—via a controllable adaptor layer. Still preclinical; flag COI and pending first-in-human safety.以可控接头层回应“硬连线”CAR-T输注后难以改向的核心局限。仍属临床前；需标注利益冲突与尚待FIH安全性验证。

City of Hope / Cancer Immunology Research (via EurekAlert) ↗ · r-2026-09-mecar

FDA approves Fayuvi (rebisufligene etisparvovec): first gene therapy for pediatric Sanfilippo syndrome type A (MPS IIIA)FDA批准Fayuvi（rebisufligene etisparvovec）：首个儿科圣菲利波综合征A型（MPS IIIA）基因治疗

2026-09-17breakthroughGenetic遗传

U.S. FDA (17 Sep 2026 approval letter STN BL 125845/0; FDA.gov / Ultragenyx): Fayuvi (rebisufligene etisparvovec-hopf) is the first approved therapy for neurologic manifestations of MPS IIIA (Sanfilippo type A) in pediatric patients with preserved neurodevelopmental function. One-time IV AAV9 vector delivers a working SGSH gene so cells can produce sulfamidase and reduce heparan sulfate buildup. Open-label multicenter study: treated children aged 2–5 maintained or improved cognitive scores versus an untreated historical control (expected plateau/decline). Common AEs (>5%) include AST elevation, nausea/vomiting, fever, decreased appetite, cytopenias, and increased amylase; labeled risks include thrombotic microangiopathy (TMA) and theoretical insertional tumorigenesis with AAV products. Orphan/Fast Track/Breakthrough designations. Not a China/Asia approval.美国FDA（2026年9月17日批准函 STN BL 125845/0；FDA.gov/Ultragenyx）：Fayuvi（rebisufligene etisparvovec-hopf）为首个获批用于有保留神经发育功能的儿科MPS IIIA（圣菲利波A型）神经表现的疗法。单次静脉AAV9载体递送可用SGSH基因，使细胞产生硫酰胺酶并减少硫酸乙酰肝素蓄积。开放标签多中心研究：2–5岁患儿认知评分相对未治疗历史对照维持或改善（自然病程预期为平台期后下降）。常见不良反应（>5%）包括AST升高、恶心呕吐、发热、食欲下降、血细胞减少与淀粉酶升高；标签风险含血栓性微血管病（TMA）及AAV产品理论插入致瘤性。获孤儿药/快速通道/突破性疗法认定。非中国/亚洲上市批准。

Why it matters: 为何重要：First disease-modifying gene therapy for a devastating pediatric lysosomal storage disorder—benchmark for CNS-targeted AAV programs. Flag historical-control design, TMA risk, and that long-term cognitive durability and insertional safety still need follow-up.首个针对毁灭性儿科溶酶体贮积病的疾病修饰基因治疗，可作为中枢靶向AAV管线标杆。需标注历史对照设计、TMA风险，以及长期认知持久性与插入安全性仍待随访。

U.S. FDA ↗ · r-2026-09-fayuvi

Zhejiang University SAHZU: Chinese closed-loop spinal interface helps 12-year-old regain assisted walking浙大二院：国产闭环脊髓神经接口助12岁女孩恢复辅助行走

2026-09-16breakthroughChina/Asia中国/亚洲medium

Zhejiang University Second Affiliated Hospital (SAHZU) reports (16 Sep 2026) that Vera, a 12-year-old Russian patient with incomplete spinal cord injury, became the first international recipient of a China-developed closed-loop spinal cord neural interface (epidural stimulation + AI-assisted parameter tuning). One month post-op she stood with support; by three months she stepped with a walker under voluntary control. SAHZU says >20 SCI patients have received the implant since the first China case (Mar 2025). Hospital/university communications—not a peer-reviewed outcomes trial; functional recovery varies and long-term durability is unproven.浙江大学医学院附属第二医院（2026年9月16日）通报：不完全性脊髓损伤的12岁俄罗斯患者Vera成为国产闭环脊髓神经接口（硬膜外刺激+AI辅助参数优化）首位国际受术者。术后1个月可辅助站立，约3个月可在自主控制下借助助行器迈步。院方称自2025年3月国内首例以来已为逾20例SCI患者植入。属医院/大学通讯——非同行评议疗效试验；功能恢复因人而异，长期持久性尚未证实。

Why it matters: 为何重要：Marks a China-origin neurorehab pathway with cross-border clinical use. Evidence is institutional case reporting pending controlled outcome data.标志中国原创神经康复路径进入跨境临床应用。证据为机构病例通报，尚待对照结局数据。

Zhejiang University / SAHZU ↗ · r-2026-09-zju-spinal

Xijing Hospital reports orthotopic gene-edited pig-to-human liver xenotransplant (brain-deceased recipient)西京医院报告基因编辑猪肝原位异种移植（脑死亡受者）

2026-09-16breakthroughChina/Asia中国/亚洲Genetic遗传Immune免疫

Nature Biomedical Engineering (16 Sep 2026) describes orthotopic transplant of a 6-gene-edited porcine liver into a brain-deceased human. Over 11 days the xenograft produced albumin and bile and supported hemodynamics; late decline linked to microthrombosis, thrombocytopenia, and coagulopathy. Scant T/B infiltration but prominent innate immunity and IgM-complement activation.《Nature Biomedical Engineering》（2026年9月16日）描述将六基因编辑猪肝原位移植入脑死亡人体。11天内移植物可产生白蛋白与胆汁并支持血流动力学；后期衰退与微血栓、血小板减少及凝血病相关。T/B细胞浸润少，但固有免疫与IgM介导补体激活显著。

Why it matters: 为何重要：Orthotopic liver xenotransplantation is a major unmet step. Genetic donor engineering must be paired with better control of innate immunity, thrombosis, and coagulation before living-patient translation.原位肝异种移植是关键未满足步骤。供体基因工程须与更好的固有免疫、血栓与凝血控制相结合，才可走向活体临床转化。

Nature Biomedical Engineering ↗ · r-2026-09-xeno-liver

Adolescent hemophilia B gene therapy BBM-H901 shows safety and efficacy in Chinese teens青少年血友病B基因治疗BBM-H901在中国青少年中显示安全有效

2026-09-16breakthroughChina/Asia中国/亚洲Genetic遗传Immune免疫

Nature Medicine (16 Sep 2026) reports China multicenter phase 1 of AAV FIX-Padua BBM-H901 in 11 adolescents aged 12–18 (NCT05709288). No dose-limiting toxicity; mean FIX:C at week 52 was 41.8 IU/dL; ABR fell from 13.9 to 0.5. Includes single-cell immune profiling; one transient liver-enzyme elevation resolved with intensified immunosuppression.《Nature Medicine》（2026年9月16日）报告中国多中心一期研究：11名12–18岁重症/中重型血友病B青少年接受AAV FIX-Padua基因治疗BBM-H901（NCT05709288）。无剂量限制毒性；第52周平均FIX:C 41.8 IU/dL；年化出血率自13.9降至0.5。含单细胞免疫分析；一例肝酶一过性升高经加强免疫抑制后缓解。

Why it matters: 为何重要：Prior FIX-Padua approvals focused on adults; this fills an adolescent evidence gap and highlights post-AAV immune/hepatic monitoring needs.既往FIX-Padua获批与试验多集中于成人；本研究填补青少年证据缺口，并强调AAV给药后免疫与肝功能监测的重要性。

Nature Medicine ↗ · r-2026-09-bbm-h901

Nature Biotechnology: Decree 818 success hinges on consistent application and AE reporting《Nature Biotechnology》：818号令成败系于一致执行与不良事件报告

2026-09-15milestoneChina/Asia中国/亚洲Genetic遗传Immune免疫

Nature Biotechnology Comment (15 Sep 2026) argues China’s Decree 818 aims to bring hospital-based cell, gene and individualized therapies into clinic safely; success depends on consistent application and whether adverse outcomes are reported, keeping institutions accountable.《Nature Biotechnology》评论（2026年9月15日）指出中国818号令旨在安全推进医院端细胞、基因与个体化疗法临床转化；成败取决于一致适用以及不良结局是否报告，使机构对结果负责。

Why it matters: 为何重要：Connects regulation design to real-world accountability—directly relevant after 2026 gene-therapy fatality disclosures.将监管设计与真实世界问责相连——在2026年基因治疗死亡披露后尤为相关。

Institutions: 机构：SJTUSM交大医学院

Nature Biotechnology ↗ · r-2026-09-nbt-818

India’s Draft National Health Research Policy 2026 frames genomics, AI, and UHC-aligned research印度《国家健康研究政策2026》草案勾勒基因组学、AI与全民健康覆盖对齐的研究体系

2026-09-11milestoneChina/Asia中国/亚洲Genetic遗传medium

Indian Journal of Orthopaedics commentary (11 Sep 2026) summarizes Draft NHRP 2026 priorities: biomedical/clinical/public-health research, digital health, AI, genomics, implementation science, aligned with Ayushman Bharat Digital Mission and Viksit Bharat 2047.《Indian Journal of Orthopaedics》评论（2026年9月11日）概括NHRP 2026草案重点：生物医学/临床/公卫研究、数字健康、AI、基因组学、实施科学，并与阿尤什曼数字健康使命及“发达印度2047”对齐。

Why it matters: 为何重要：Signals South Asia’s push to modernize health R&D governance alongside China’s rapid biomedicine scale-up.表明南亚在推动健康研发治理现代化，与中国生物医药快速扩容形成区域对照。

Indian Journal of Orthopaedics ↗ · r-2026-09-india-nhrp

Alix Earle family: mother BRCA2+ breast cancer; both daughters test positive (Netflix / Glamour)Alix Earle一家：母亲BRCA2阳性乳腺癌；两姐妹检测均阳性（Netflix/Glamour）

2026-09-10individualGenetic遗传

Glamour (10 Sep 2026) and related coverage of Netflix’s Earle Meets World describe Alisa Maniaci’s BRCA2-associated breast cancer (mastectomy pathway) and genetic counseling for daughters Alix (25) and Ashtin (23)—both tested positive for the same pathogenic BRCA2 variant. The sisters discuss intensified screening timelines, fertility/egg-freezing considerations, and possible future risk-reducing surgery. Family public disclosure for awareness—not new biomedical data.《Glamour》（2026年9月10日）及Netflix纪录片《Earle Meets World》相关报道：母亲Alisa Maniaci因BRCA2相关乳腺癌（含乳房切除路径），女儿Alix（25岁）与Ashtin（23岁）经遗传咨询后均检出同一致病性BRCA2变异。姐妹讨论强化筛查时间表、生育/冻卵考量及未来风险降低手术可能。属家庭公开披露以提高认知——非新的生物医学数据。

Why it matters: 为何重要：Parent–child BRCA2 narrative matches briefing priority on famous genetic family cases and cascade testing education.亲子BRCA2叙事契合简报对知名遗传家系案例与级联检测科普的优先方向。

Glamour ↗ · r-2026-09-earle-brca2

Chinese neuroprotectant loberamisal extends ischemic-stroke window to 48 hours in phase 3 LAIS中国神经保护剂洛贝拉米萨在LAIS三期试验中将缺血性卒中治疗窗延长至48小时

2026-09-10breakthroughChina/Asia中国/亚洲

JAMA (online 10 Sep 2026) reports the LAIS phase 3 RCT: 998 adults with acute ischemic stroke within 48 hours at 32 Chinese hospitals received IV loberamisal 40 mg daily for 10 days vs placebo plus standard care. At 90 days, 69.7% vs 56.3% achieved mRS 0–1 (RR 1.24; risk difference +13.28 pp). Serious AEs and mortality were numerically similar.《JAMA》（2026年9月10日在线）发布LAIS三期随机对照试验：中国32家医院998例发病48小时内急性缺血性卒中患者，静脉洛贝拉米萨40 mg/日×10天对比安慰剂+标准治疗。90天时mRS 0–1比例为69.7%对56.3%（RR 1.24；风险差+13.28个百分点）。严重不良事件与死亡率两组相近。

Why it matters: 为何重要：Reperfusion is typically limited to ~6 hours; a China-only phase 3 neuroprotection signal within 48 hours could reshape acute stroke pathways if replicated and approved, given China’s large stroke burden.再灌注治疗通常限于约6小时；若这一仅在中国完成的三期神经保护阳性结果可被复现并获批，鉴于中国卒中负担巨大，或将重塑急性卒中救治路径。

Institutions: 机构：PKU Health北大医学部

JAMA / LAIS Investigators ↗ · r-2026-09-lais

Nature Medicine: real-world lessons from an AI-agent eye clinic deployed in China《Nature Medicine》：中国部署AI智能体眼科诊所的真实世界经验

2026-09-10public-healthChina/Asia中国/亚洲

A Nature Medicine Comment (10 Sep 2026) from Tsinghua-led teams describes initial real-world implementation of an AI-agent eye clinic in China, arguing AI-native care needs workflow integration, clinician engagement, and measurable clinical value—not only model performance.清华团队在《Nature Medicine》评论（2026年9月10日）中描述中国AI智能体眼科诊所的初步真实世界落地，指出从AI辅助走向AI原生诊疗需要流程整合、临床医师参与与可度量临床价值，而非仅模型性能。

Why it matters: 为何重要：Asia’s eye-disease burden is large; scalable AI clinics could expand screening, but this is an implementation comment—not a pivotal outcomes RCT.亚洲眼病负担沉重；可扩展AI诊所或可扩大筛查能力，但本文为实施评论而非关键结局RCT，人群影响结论宜审慎。

Institutions: 机构：Tsinghua Med/Life清华医学/生科

Nature Medicine ↗ · r-2026-09-ai-eye

Lancet Microbe: bacterial co-detection common in community viral ARI via China DTC testing《Lancet Microbe》：中国直销检测平台显示社区病毒性急性呼吸道感染细菌共检出常见

2026-09-09public-healthChina/Asia中国/亚洲Immune免疫

Lancet Microbe (9 Sep 2026): large all-age community DTC multiplex respiratory pathogen database across China. Among M. pneumoniae–positive cases, bacterial co-detection ~50%; associations with S. pneumoniae and H. influenzae vary by virus (e.g., IBV, SARS-CoV-2).《Lancet Microbe》（2026年9月9日）：基于中国跨地区全年龄社区直销多联呼吸道病原检测大数据。肺炎支原体阳性者中细菌共检出约半数；与肺炎链球菌、流感嗜血杆菌等共检出风险因病毒（如乙型流感、SARS-CoV-2）而异。

Why it matters: 为何重要：Community-level co-pathogen epidemiology informs antibiotic stewardship and seasonal respiratory preparedness in China.社区层面共病原流行病学为中国抗生素合理使用与季节性呼吸道疫情准备提供依据。

The Lancet Microbe ↗ · r-2026-09-lancet-ari

Nature explainer: China’s Order 818 tightens oversight of biomedical IITs after child deaths《Nature》解读：儿童死亡后中国818号令收紧生物医学研究者发起试验监管

2026-09-08public-healthChina/Asia中国/亚洲Genetic遗传Immune免疫

Nature News Explainer (8 Sep 2026): State Council Order 818 (effective 1 May 2026) adds national NHC oversight to hospital ethics–approved IITs for cell/gene/new biomedical technologies—second assessment possible, power to suspend/alter/cancel. IITs in cell/gene grew ~11-fold (2015–2023).《Nature》新闻解读（2026年9月8日）：国务院818号令（2026年5月1日生效）对医院伦理已批的细胞/基因等新生物医学技术IIT增加国家卫健委层监管——可二次评估，可暂停/变更/终止。2015–2023细胞基因IIT约增11倍。

Why it matters: 为何重要：Policy landmark balancing China’s dual-track innovation speed with patient safety; enforcement quality remains the open question.在创新速度与患者安全间再平衡的政策里程碑；执行质量仍是开放问题。

Institutions: 机构：SJTUSM交大医学院

Nature ↗ · r-2026-09-order818

Shanghai tBE base-editing therapy: durable remission in SCD and β-thalassemia across African/Asian genotypes上海tBE碱基编辑疗法：非洲与亚洲基因型镰贫/β地贫获持久缓解

2026-09-07breakthroughChina/Asia中国/亚洲Genetic遗传

Cell Stem Cell (online 7 Sep 2026; DOI 10.1016/j.stem.2026.08.009) reports transformer Base Editor therapies CS-101/CS-206. After prior Chinese TDT success, four additional patients (SCD Nigeria; TDT Laos, Malaysia, Pakistan) achieved transfusion independence or VOC freedom, high HbF, no reported off-target edits. Sponsor states >30 patients treated with high clinical success—program-wide tallies partly company-communicated.《Cell Stem Cell》（2026年9月7日在线；DOI 10.1016/j.stem.2026.08.009）报告tBE疗法CS-101/CS-206。继中国输血依赖型地贫队列后，另4例（尼日利亚镰贫；老挝、马来西亚、巴基斯坦地贫）获持续输血独立或无血管阻塞危象、高HbF，未见报告脱靶。申办方称逾30例治疗临床成功率高——整体人数部分来自公司沟通。

Why it matters: 为何重要：β-thalassemia is highly prevalent in southern China and SE/South Asia; multi-ancestry base-editing data strengthen a China-origin genetic therapy case. Flag sponsor-tallied patient counts beyond the peer-reviewed extension cohort.β地贫在中国南方与东南亚/南亚高发；跨族群碱基编辑数据强化中国源头基因疗法价值。需注意：超出同行评议扩展队列的患者总数含申办方沟通信息。

Institutions: 机构：Ruijin瑞金

Cell Stem Cell / CorrectSequence ↗ · r-2026-09-tbe

Singapore rapper Sheikh Haikel discloses stage-4 colon cancer; tests indicate non-hereditary disease新加坡说唱歌手Sheikh Haikel公开四期结肠癌；检测提示非遗传性

2026-09-06individualChina/Asia中国/亚洲Genetic遗传

In early Sep 2026, Singapore rapper-entrepreneur Sheikh Haikel (50) went public about stage-4 colon cancer metastatic to liver. Delayed colonoscopy after rectal bleeding from late 2023; diagnosed Sep 2025; chemo and four major abdominal operations; ~100 kg weight loss. He said blood tests showed non-hereditary disease. Interview journalism, not a medical case report.2026年9月初，新加坡说唱企业家Sheikh Haikel（50岁）公开其肝转移四期结肠癌历程。2023年末起便血却推迟肠镜，2025年9月确诊，化疗并四次大型腹部手术，体重下降约100公斤。其称血液检测提示非遗传性。属访谈报道，非医学病例报告。

Why it matters: 为何重要：High-profile Asian case spotlighting delayed colorectal screening, late presentation, and family communication of hereditary vs sporadic risk.高关注度亚洲个案，凸显结直肠癌筛查延误、晚期就诊，以及遗传性与散发性风险对家庭沟通的意义。

Institutions: 机构：NUS Medicine国大医学 · NUH国大医院

The Star (Straits Times/ANN) ↗ · r-2026-09-haikel

NUS: drug candidate targets DP103 ‘master switch’ in triple-negative breast cancer (preclinical)新加坡国立大学：候选药物靶向三阴性乳腺癌DP103“总开关”（临床前）

2026-08-18breakthroughChina/Asia中国/亚洲Genetic遗传medium

NUS Medicine press materials (18 Aug 2026) and Straits Times coverage describe identification of DP103 as a master regulator in TNBC and activity of RX-5902 in turning off that switch in preclinical models—early-stage research, not a clinical approval.新加坡国立大学医学院新闻稿（2026年8月18日）及《海峡时报》报道称识别DP103为三阴性乳腺癌主调控因子，RX-5902在临床前模型中可关闭该开关——属早期研究，非临床获批。

Why it matters: 为何重要：TNBC disproportionately affects younger women in Asia; new target biology matters but needs clinical translation.三阴性乳腺癌在亚洲较年轻女性中负担突出；新靶点生物学重要，但仍待临床转化。

Institutions: 机构：NUS Medicine国大医学

NUS Medicine / Straits Times ↗ · r-2026-08-nus-tnbc

Korea national polypharmacy program cuts 90-day readmission in hospitalized older adults韩国国家多重用药管理项目降低住院老年人90天再入院

2026-08-08public-healthChina/Asia中国/亚洲

Drugs & Aging (8 Aug 2026): retrospective cohort across 34 hospitals; intervention vs control (~1135 vs 1125). Adjusted HR for 90-day readmission 0.85 (95% CI 0.75–0.96); lower hospitalization costs; payer benefit–cost ratio ~3.8.《Drugs & Aging》（2026年8月8日）：34家医院回顾性队列，干预组与对照组约1135对1125。90天再入院校正HR 0.85（95% CI 0.75–0.96）；住院费用更低；支付方效益成本比约3.8。

Why it matters: 为何重要：Aging East Asia faces polypharmacy harm; national medication-management programs show clinical and economic return.东亚老龄化面临多重用药伤害；国家级用药管理项目显示临床与经济双重回报。

Drugs & Aging ↗ · r-2026-08-korea-poly

Two child deaths in Chinese gene-editing/gene-therapy trials renew transparency and IIT oversight debate中国基因编辑/基因治疗试验两例儿童死亡再掀透明度与研究者发起试验监管讨论

2026-08-05public-healthChina/Asia中国/亚洲Genetic遗传

Nature and CNN (Jul–Aug 2026) reported two child deaths linked to separate Chinese experimental gene therapies: a girl in a Shanghai Jiao Tong/Xinhua Hospital trial (death disclosed via Science/Retraction Watch investigation) and a boy in a HuidaGene trial (company announced Aug 2025 death in Aug 2026). Universities launched investigations; debate centers on investigator-initiated trials (IITs) and disclosure.《Nature》与CNN（2026年7–8月）报道两例与中国试验性基因治疗相关的儿童死亡：一例上海交大/新华医院试验中的女孩（经Science/Retraction Watch调查披露），一例慧大基因试验中的男孩（公司2026年8月公布2025年死亡）。高校启动调查；焦点在研究者发起试验（IIT）与不良结局披露。

Why it matters: 为何重要：Shows the safety/transparency cost of fast biomedical translation; frames why Decree/Order 818 and adverse-event reporting matter for China’s cell/gene sector reputation.揭示生物医药快速转化中的安全与透明度代价；说明818号令与不良事件报告对中国细胞/基因产业信誉的关键性。

Institutions: 机构：SJTUSM交大医学院

Nature / CNN ↗ · r-2026-08-gene-deaths

Archive — browse by decade档案 — 按年代浏览

36

China adds HPV vaccine to National Immunization Programme — free bivalent for eligible 13-year-old girls中国将HPV疫苗纳入国家免疫规划——适龄13岁女孩免费双价接种

2025-11-10public-healthChina/Asia中国/亚洲Immune免疫

From 10 Nov 2025 China provides two free doses of bivalent HPV vaccine to girls born on/after 10 Nov 2011 who reach age 13—historic step toward cervical-cancer elimination goals; WHO Congratulated the decision.自2025年11月10日起，中国为2011年11月10日及以后出生且满13岁女孩免费接种2剂双价HPV疫苗——迈向消除宫颈癌目标的历史性步骤；WHO祝贺该决定。

Why it matters: 为何重要：Closes a long-standing NIP gap vs WHO-recommended vaccines; major China women’s-health equity advance.弥补相对WHO推荐疫苗的长期国家免疫规划缺口；中国女性健康公平重大进展。

WHO / China government ↗ · a-2025-hpv-nip

China CDC technical plan for HPV NIP implementation published中国疾控发布HPV纳入国家免疫规划实施技术方案

2025-10-30milestoneChina/Asia中国/亚洲Immune免疫

China CDC issued the implementation technical scheme for HPV NIP rollout (two-dose bivalent against types 16/18), guiding provincial procurement, cold chain, school coordination and coverage monitoring.中国疾控发布HPV国家免疫规划实施技术方案（针对16/18型的双价两剂次），指导省级采购、冷链、学校协作与接种率监测。

Why it matters: 为何重要：Operational companion to the Nov 2025 policy—determines real coverage.2025年11月政策的操作配套——决定真实覆盖率。

China CDC ↗ · a-2025-hpv-gov

Belief BioMed BBM-H901 NMPA approval for adult hemophilia B (Asia FIX-Padua AAV)信念医药BBM-H901获NMPA批准用于成人血友病B（亚洲FIX-Padua AAV）

2025-04-01milestoneChina/Asia中国/亚洲Genetic遗传Immune免疫medium

China’s approval of BBM-H901 for adults with hemophilia B established a domestic AAV FIX-Padua product, later extended by 2026 adolescent Nature Medicine data.中国批准BBM-H901用于成人血友病B，确立国产AAV FIX-Padua产品，其后由2026年青少年《Nature Medicine》数据延伸。

Why it matters: 为何重要：China gene-therapy commercialization milestone linking to 2026 adolescent trial.中国基因治疗商业化里程碑，衔接2026年青少年试验。

Company / industry reports ↗ · a-2025-bbm-h901-nmpa

Nobel Prize in Chemistry 2024: AlphaFold / protein design (Hassabis, Jumper, Baker)2024年诺贝尔化学奖：AlphaFold/蛋白质设计（Hassabis、Jumper、Baker）

2024-10-09individual

Chemistry Nobel recognized computational protein design and structure prediction—tools now embedded in Asia biotech pipelines for antibody and enzyme engineering.化学诺奖表彰计算蛋白质设计与结构预测——工具已嵌入亚洲生物技术管线的抗体与酶工程。

Why it matters: 为何重要：Individual/scientific recognition of AI methods transforming biomedicine.对变革生物医药的AI方法的个人/科学认可。

Nobel Prize ↗ · a-2024-nobel-ai

AlphaFold 3 / Nature: AI predicts complexes of proteins, DNA, RNA and ligandsAlphaFold 3 /《Nature》：AI预测蛋白、DNA、RNA与配体复合物

2024-05-08breakthroughGenetic遗传

DeepMind’s AlphaFold 3 paper extended structure prediction to biomolecular complexes, accelerating drug discovery workflows adopted by Asia pharma and academic labs.DeepMind的AlphaFold 3论文将结构预测扩展至生物分子复合物，加速亚洲药企与实验室采用的药物发现流程。

Why it matters: 为何重要：AI–structural biology convergence reshaping how genetic targets become drugs.AI与结构生物学融合，重塑遗传靶点成药路径。

Nature ↗ · a-2024-alphafold3

FDA approves Casgevy for sickle cell diseaseFDA批准Casgevy治疗镰状细胞病

2023-12-08milestoneGenetic遗传

US approval of Casgevy for SCD in patients ≥12 with recurrent VOCs marked CRISPR’s entry into mainstream US therapeutics.美国批准Casgevy用于≥12岁复发性血管阻塞危象镰贫患者，标志CRISPR进入美国主流治疗。

Why it matters: 为何重要：Anchors the gene-editing therapy market that Asia innovators now compete in.锚定亚洲创新者正在竞争的基因编辑治疗市场。

Institutions: 机构：Broad布罗德

FDA / Vertex-CRISPR ↗ · a-2023-casgevy-fda

UK MHRA approves Casgevy — world’s first CRISPR-based therapy (TDT, then SCD)英国MHRA批准Casgevy——全球首个CRISPR疗法（地贫，其后镰贫）

2023-11-16breakthroughGenetic遗传

Exagamglogene autotemcel (Casgevy) became the first approved CRISPR/Cas9 medicine (UK, Nov 2023 for TDT), followed by FDA SCD approval Dec 2023—validating therapeutic genome editing.exagamglogene autotemcel（Casgevy）成为首个获批CRISPR/Cas9药物（英国2023年11月地贫适应症），FDA于2023年12月批准镰贫——验证治疗性基因组编辑。

Why it matters: 为何重要：Proof that CRISPR can be a medicine; benchmark for China’s base-editing hemoglobinopathy programs.证明CRISPR可成药；为中国碱基编辑血红蛋白病项目提供对标。

Institutions: 机构：Broad布罗德

CRISPR Therapeutics / Vertex ↗ · a-2023-casgevy-uk

FDA approves first RSV vaccines for older adults (Arexvy) — new respiratory prevention eraFDA批准首个老年人RSV疫苗（Arexvy）——呼吸道预防新时代

2023-05-03breakthroughImmune免疫

GSK’s Arexvy became the first approved RSV vaccine for older adults, followed by Abrysvo and infant nirsevimab strategies—relevant as East Asia ages rapidly.GSK的Arexvy成为首个获批老年人RSV疫苗，其后有Abrysvo与婴儿nirsevimab策略——对快速老龄化的东亚尤为相关。

Why it matters: 为何重要：Extends immunization beyond classic pediatric schedules into adult respiratory protection.将免疫接种从经典儿科程序延伸至成人呼吸道保护。

FDA ↗ · a-2023-rsv

WHO declares mpox (monkeypox) a PHEIC amid 2022 multi-country outbreakWHO在2022年多国暴发中宣布猴痘（mpox）为PHEIC

2022-07-23public-healthImmune免疫

The 2022 mpox PHEIC tested post-COVID surveillance and vaccination (MVA-BN) deployment; Asia jurisdictions implemented targeted responses.2022年猴痘PHEIC检验后新冠监测与疫苗（MVA-BN）部署；亚洲司法管辖区实施靶向应对。

Why it matters: 为何重要：Reminder that non-respiratory orthopox threats also need Asia preparedness.提醒非呼吸道正痘病毒威胁亦需亚洲准备度。

WHO ↗ · a-2022-monkeypox

University of Maryland: first gene-edited pig heart transplant into a living human (David Bennett)马里兰大学：首例基因编辑猪心移植入活体人类（David Bennett）

2022-01-07breakthroughGenetic遗传Immune免疫

Historic xenotransplant of a 10-gene-edited porcine heart into a living patient; recipient survived 60 days. Framed innate immunity, zoonosis, and coagulation challenges later echoed in China’s 2026 liver xeno work.历史性将十基因编辑猪心移植入活体患者；受者存活60天。凸显固有免疫、人畜共患病与凝血挑战，其后在中国2026肝异种移植工作中再现。

Why it matters: 为何重要：Global xenotransplant inflection informing Asia programs including Xijing liver study.全球异种移植拐点，影响包括西京肝研究在内的亚洲项目。

University of Maryland Medical Center ↗ · a-2022-pig-heart

WHO certifies China malaria-freeWHO认证中国消除疟疾

2021-06-30public-healthChina/Asia中国/亚洲Immune免疫

After decades of control descending from the 1950s campaigns and artemisinin-era therapy, WHO certified China malaria-free in Jun 2021—zero indigenous cases for consecutive years.历经自1950年代运动与青蒿素时代疗法以来的数十年防控，WHO于2021年6月认证中国消除疟疾——连续多年无本地感染病例。

Why it matters: 为何重要：Capstone Asia public-health achievement linking Tu Youyou’s science to national elimination.连接屠呦呦科学与国家消除的亚洲公卫巅峰成就。

Institutions: 机构：CAMS / PUMC医科院/协和医学院

WHO ↗ · a-2021-malaria-china

NMPA approves axicabtagene ciloleucel (Yescarta) — first CAR-T approved in mainland ChinaNMPA批准axicabtagene ciloleucel（Yescarta）——中国内地首个获批CAR-T

2021-06-22milestoneChina/Asia中国/亚洲Genetic遗传Immune免疫

Fosun Kite’s Yescarta gained NMPA approval for relapsed/refractory large B-cell lymphoma, inaugurating commercial CAR-T availability in mainland China and accelerating domestic competitors.复星凯特Yescarta获NMPA批准用于复发/难治大B细胞淋巴瘤，开启中国内地商业CAR-T可及并加速国产竞品。

Why it matters: 为何重要：Regulatory beachhead for China’s now-crowded CAR-T landscape culminating in solid-tumor approvals.中国如今拥挤的CAR-T格局的监管滩头，终至实体瘤获批。

Institutions: 机构：Ruijin瑞金

GeneOnline / company releases ↗ · a-2021-yescarta-china

WHO Emergency Use Listing for Sinovac CoronaVacWHO将科兴CoronaVac列入紧急使用清单

2021-06-01milestoneChina/Asia中国/亚洲Immune免疫

WHO granted EUL to Sinovac’s CoronaVac on 1 Jun 2021, enabling UN procurement channels and wider use across Asia, Latin America and Africa—though later evidence on variant protection and boosting evolved.WHO于2021年6月1日给予科兴CoronaVac紧急使用认证，打通联合国采购渠道并扩大亚洲、拉美与非洲使用——其后关于变异株保护与加强针的证据持续演变。

Why it matters: 为何重要：Made a China-made vaccine a pillar of global supply equity debates.使中国产疫苗成为全球供应公平辩论的支柱之一。

WHO ↗ · a-2021-coronavac-who

China grants conditional approval to Sinopharm BBIBP-CorV COVID-19 vaccine中国附条件批准国药集团BBIBP-CorV新冠疫苗

2020-12-31breakthroughChina/Asia中国/亚洲Immune免疫

China’s NMPA granted conditional marketing authorization to Sinopharm’s inactivated BBIBP-CorV at end-2020, anchoring domestic mass vaccination before many Western rollouts fully scaled.中国NMPA于2020年底附条件批准国药灭活疫苗BBIBP-CorV，在许多西方大规模接种全面铺开前支撑国内大规模接种。

Why it matters: 为何重要：Core of China’s early immunization campaign and later COVAX/export discussions.中国早期免疫运动核心，并进入其后COVAX/出口讨论。

Xinhua / NMPA reports ↗ · a-2020-sinopharm

FDA EUA for Pfizer–BioNTech mRNA COVID-19 vaccine — platform proof at pandemic speedFDA紧急授权辉瑞–BioNTech mRNA新冠疫苗——大流行速度验证平台

2020-12-11breakthroughGenetic遗传Immune免疫

First authorized mRNA vaccine in the US demonstrated that nucleoside-modified mRNA–LNP platforms can deliver rapid, high-efficacy immunization—technology later pursued across Asia manufacturing strategies.美国首个获授mRNA疫苗证明核苷修饰mRNA–脂质纳米粒平台可实现快速高效免疫——其后亚洲多国纳入制造战略。

Why it matters: 为何重要：Genetic-medicine adjacent platform that permanently changed vaccine R&D expectations.与基因药物相邻的平台，永久改变疫苗研发预期。

FDA ↗ · a-2021-mrna

WHO declares COVID-19 a pandemic — pathogen first characterized in WuhanWHO宣布COVID-19大流行——病原体最初在武汉被表征

2020-03-11public-healthChina/Asia中国/亚洲Immune免疫

After the Dec 2019 Wuhan cluster and global spread, WHO characterized COVID-19 as a pandemic on 11 Mar 2020, triggering unprecedented vaccine, antiviral, and public-health mobilization including China’s zero-COVID then reopening phases.2019年12月武汉聚集性疫情与全球扩散后，WHO于2020年3月11日将COVID-19定性为大流行，触发空前疫苗、抗病毒与公卫动员，包括中国动态清零与其后开放阶段。

Why it matters: 为何重要：Defining public-health event of the 20-year window; reshaped Asia health systems and biomedicine investment.20年窗口内决定性公卫事件；重塑亚洲卫生体系与生物医药投资。

WHO ↗ · a-2020-covid-declare

FDA approves onasemnogene abeparvovec (Zolgensma) for SMA — high-dose AAV gene therapy landmarkFDA批准onasemnogene abeparvovec（Zolgensma）治疗SMA——高剂量AAV基因治疗里程碑

2019-05-24breakthroughGenetic遗传

One-time AAV9 gene therapy for spinal muscular atrophy highlighted both transformative efficacy and the cost/access challenges of genetic medicines—issues Asia health systems still navigate.一次性AAV9基因治疗脊髓性肌萎缩症，凸显变革性疗效与基因药物可及/费用挑战——亚洲卫生体系仍在应对。

Why it matters: 为何重要：Template for pricing, newborn screening linkage, and AAV safety monitoring debates worldwide.全球定价、新生儿筛查衔接与AAV安全监测辩论的范本。

Institutions: 机构：NIHNIH

FDA ↗ · a-2019-zolgensma

China approves toripalimab — early domestic PD-1 antibody commercialization中国批准特瑞普利单抗——国产PD-1抗体早期商业化

2018-12-17breakthroughChina/Asia中国/亚洲Immune免疫medium

Toripalimab (Junshi) was among the first domestically developed PD-1 mAbs approved in China, launching a wave of Chinese checkpoint inhibitors that later sought FDA indication expansions.特瑞普利单抗（君实）为中国最早获批的国产PD-1单抗之一，开启中国检查点抑制剂浪潮，其后寻求FDA适应症拓展。

Why it matters: 为何重要：Marks China’s shift from PD-1 follower to competitive immuno-oncology producer.标志中国从PD-1跟随者转向有竞争力的免疫肿瘤生产国。

Institutions: 机构：SYSUCC中肿

Junshi / NMPA reports ↗ · a-2020-toripalimab

He Jiankui announces CRISPR-edited babies — global condemnation and governance reset贺建奎宣布CRISPR编辑婴儿——全球谴责与治理重置

2018-11-26individualChina/Asia中国/亚洲Genetic遗传Immune免疫

At the Second International Summit on Human Genome Editing, He Jiankui claimed birth of twin girls with CCR5 edits intended for HIV resistance. The experiment was widely condemned as unethical; China later imprisoned He and tightened germline-editing rules.在第二届国际人类基因组编辑峰会上，贺建奎宣称诞生经CCR5编辑以期抗HIV的双胞胎女婴。实验被广泛谴责为不伦理；中国其后判处其刑罚并收紧生殖系编辑规则。

Why it matters: 为何重要：Cautionary individual milestone that still shapes China’s biomedical ethics and 2020s regulations (including later Order 818 context).警示性个人里程碑，持续塑造中国生物医学伦理与2020年代监管（含其后818号令语境）。

Nature ↗ · a-2018-he-jiankui

Nobel Prize: James Allison & Tasuku Honjo for cancer therapy by inhibition of negative immune regulation诺贝尔奖：Allison与本庶佑因抑制负性免疫调节的癌症疗法获奖

2018-10-01individualImmune免疫

The 2018 Medicine Nobel recognized CTLA-4 and PD-1 checkpoint discoveries that enabled modern immunotherapy—Honjo’s Japan base underscoring Asia’s role in foundational immune science.2018年医学诺奖表彰CTLA-4与PD-1检查点发现，奠基现代免疫治疗——本庶佑的日本根基凸显亚洲在基础免疫科学中的角色。

Why it matters: 为何重要：Scientific legitimization of checkpoint blockade that China industry scaled into multiple domestic PD-1s.检查点阻断的科学正名，中国工业界将其规模化为多种国产PD-1。

Institutions: 机构：Kyoto U京大 · MD Anderson安德森 · MSKMSK · NCC Japan日本国立癌症中心

Nobel Prize ↗ · a-2018-nobel-immuno

FDA approves Luxturna — first in vivo AAV gene therapy for inherited retinal diseaseFDA批准Luxturna——首个遗传性视网膜病体内AAV基因治疗

2017-12-19breakthroughGenetic遗传

Voretigene neparvovec (Luxturna) approval validated in vivo AAV gene therapy for RPE65-mediated retinal dystrophy, setting regulatory templates used worldwide including Asia submissions.voretigene neparvovec（Luxturna）获批验证RPE65介导视网膜营养不良的体内AAV基因治疗，确立包括亚洲申报在内的全球监管范本。

Why it matters: 为何重要：Opened the modern gene-therapy approval pathway later used for hemophilia and neuromuscular products.开启现代基因治疗获批路径，其后用于血友病与神经肌肉产品。

Institutions: 机构：NIHNIH

FDA ↗ · a-2017-luxturna

FDA approves first CAR-T: tisagenlecleucel (Kymriah) for B-cell ALLFDA批准首个CAR-T：tisagenlecleucel（Kymriah）治疗B细胞ALL

2017-08-30breakthroughGenetic遗传Immune免疫

FDA approved the first chimeric antigen receptor T-cell therapy, opening a new class of living drugs for hematologic cancers and catalyzing a global—and especially Chinese—CAR-T development boom.FDA批准首个嵌合抗原受体T细胞疗法，开启血液肿瘤活细胞药物新类别，并催化全球尤其是中国的CAR-T研发热潮。

Why it matters: 为何重要：Immune-cell therapy milestone that China later matched with domestic products and the 2026 solid-tumor satri-cel approval.免疫细胞治疗里程碑；中国随后以国产产品及2026年实体瘤satri-cel获批跟进。

Institutions: 机构：MSKMSK

FDA ↗ · a-2017-cart-fda

First CRISPR-Cas9 clinical trial in humans begins in China (PD-1–edited T cells for NSCLC)全球首次CRISPR-Cas9人体临床试验在中国启动（PD-1编辑T细胞治疗NSCLC）

2016-10-28breakthroughChina/Asia中国/亚洲Genetic遗传Immune免疫

Team led by Lu You at West China Hospital, Sichuan University, began injecting CRISPR-edited PD-1 knockout autologous T cells into patients with metastatic non-small-cell lung cancer (NCT02793856)—widely reported as first-in-human CRISPR dosing.四川大学华西医院卢铀团队开始向转移性非小细胞肺癌患者输注CRISPR编辑的PD-1敲除自体T细胞（NCT02793856）——被广泛报道为首次人体CRISPR给药。

Why it matters: 为何重要：Put China at the frontier of clinical gene editing; also foreshadowed later ethics/safety governance debates.使中国站上临床基因编辑前沿；亦预示其后伦理与安全治理辩论。

Institutions: 机构：West China华西

Nature / Scientific American ↗ · a-2016-crispr-china

Healthy China 2030 blueprint issued — national health strategy framing two decades《“健康中国2030”规划纲要》发布——框定二十年国家健康战略

2016-10-25milestoneChina/Asia中国/亚洲

CPC Central Committee and State Council issued Healthy China 2030, elevating prevention, primary care, and Healthy China goals that later guided HPV NIP, chronic-disease control and biomedicine industrial policy.中共中央、国务院印发《“健康中国2030”规划纲要》，提升预防、基层与健康中国目标，其后指引HPV纳入免疫规划、慢病控制与生物医药产业政策。

Why it matters: 为何重要：Policy umbrella under which many China public-health and innovation milestones sit.许多中国公卫与创新里程碑所依托的政策总纲。

Institutions: 机构：PUMCH协和

China government ↗ · a-2018-healthy-china

China approves world’s first EV71 vaccine against severe hand-foot-mouth disease中国批准全球首个EV71疫苗应对重症手足口病

2015-12-03public-healthChina/Asia中国/亚洲Immune免疫medium

China’s NMPA (then CFDA) approved the world’s first enterovirus 71 vaccine to prevent severe HFMD, a major pediatric burden across East and Southeast Asia.中国药监部门批准全球首个肠道病毒71型疫苗预防重症手足口病——东亚与东南亚重要儿科负担。

Why it matters: 为何重要：Asia-specific pathogen vaccine leadership from Chinese manufacturers.中国疫苗企业针对亚洲特有病原的领导力体现。

WHO / China FDA reports ↗ · a-2018-ev71

Tu Youyou awarded Nobel Prize for artemisinin — TCM-derived global malaria therapy屠呦呦因青蒿素获诺贝尔奖——源自中医药的全球疟疾疗法

2015-10-05individualChina/Asia中国/亚洲

Chinese scientist Tu Youyou shared the 2015 Nobel Prize in Physiology or Medicine for discoveries concerning a novel therapy against malaria (artemisinin), extracted via Project 523 work that transformed global malaria treatment.中国科学家屠呦呦因发现抗疟新疗法（青蒿素）分享2015年诺贝尔生理学或医学奖；源于523任务的工作深刻改变全球疟疾治疗。

Why it matters: 为何重要：Most visible China individual biomedical Nobel of the modern era; symbol of Asia contribution to global infectious-disease control.当代中国最受瞩目的生物医学个人诺奖；象征亚洲对全球传染病控制的贡献。

Institutions: 机构：CAMS / PUMC医科院/协和医学院

Nobel Prize ↗ · a-2015-tu

FDA expands PD-1 era: Keytruda (pembrolizumab) approved — checkpoint immunotherapy mainstreamedFDA拓展PD-1时代：Keytruda（帕博利珠单抗）获批——免疫检查点疗法主流化

2014-09-04breakthroughImmune免疫

Pembrolizumab FDA approval (Sep 2014, melanoma) cemented PD-1 blockade as a pillar of oncology; China later developed multiple domestic PD-1/PD-L1 antibodies (toripalimab, sintilimab, camrelizumab, tislelizumab) reshaping Asia cancer care.帕博利珠单抗FDA获批（2014年9月，黑色素瘤）确立PD-1阻断为肿瘤学支柱；中国随后研发多种国产PD-1/PD-L1抗体（特瑞普利、信迪利、卡瑞利珠、替雷利珠等），重塑亚洲肿瘤治疗。

Why it matters: 为何重要：Immune-oncology inflection that enabled later CAR-T combinations and China PD-1 export/innovation race.免疫肿瘤拐点，为后续CAR-T联合与中国PD-1出海/创新竞赛奠基。

Institutions: 机构：MD Anderson安德森 · MSKMSK · NIHNIH · NCC Japan日本国立癌症中心

FDA / Merck ↗ · a-2013-pd1

WHO declares West Africa Ebola outbreak a PHEIC — later China vaccine/candidate contributionsWHO宣布西非埃博拉疫情为PHEIC——其后中国疫苗/候选贡献

2014-08-08public-healthImmune免疫

The 2014–2016 Ebola PHEIC accelerated vaccine platforms (rVSV-ZEBOV) and saw Chinese institutes develop Ad5-EBOV candidates, reinforcing global outbreak R&D networks involving Asia.2014–2016埃博拉PHEIC加速疫苗平台（rVSV-ZEBOV），中国机构亦开发Ad5-EBOV候选，强化有亚洲参与的全球疫情研发网络。

Why it matters: 为何重要：Showed how outbreak vaccines can move from trial to deployment—lessons reused in COVID.展示疫情疫苗从试验到部署的路径——经验在新冠中复用。

WHO ↗ · a-2014-ebola

Shinya Yamanaka (Kyoto) shares Nobel for iPS cells — Asia stem-cell landmark山中伸弥（京都）因iPS细胞分享诺奖——亚洲干细胞里程碑

2012-10-08individualChina/Asia中国/亚洲Genetic遗传

Yamanaka’s induced pluripotent stem-cell work (Nobel 2012 with Gurdon) underpins regenerative medicine programs across Japan, China and Korea still advancing toward clinical use.山中伸弥诱导多能干细胞工作（2012年与Gurdon共享诺奖）支撑日本、中国与韩国仍在推进临床应用的再生医学项目。

Why it matters: 为何重要：Foundational Asia individual contribution to genetic reprogramming medicine.亚洲个体对遗传重编程医学的奠基性贡献。

Institutions: 机构：Kyoto U京大 · RIKEN理研

Nobel Prize ↗ · a-2011-ipsc-nobel

CRISPR-Cas9 programmed DNA cleavage published — gene-editing toolkit era beginsCRISPR-Cas9可编程DNA切割论文发表——基因编辑工具时代开启

2012-06-28breakthroughGenetic遗传

Seminal work (Jinek et al., Science 2012) showed Cas9 can be programmed with guide RNA to cleave DNA, launching the CRISPR therapeutic and research wave that later reached first-in-human trials in China and global approvals.Jinek等（Science 2012）显示Cas9可经向导RNA编程切割DNA，启动CRISPR治疗与研究浪潮，其后在中国进入人体试验并在全球获批。

Why it matters: 为何重要：Platform technology behind Casgevy, China base-editing programs, and countless Asia academic trials.支撑Casgevy、中国碱基编辑项目及大量亚洲学术试验的平台技术。

Institutions: 机构：Broad布罗德 · Harvard Med哈佛医学

Science ↗ · a-2012-crispr

China approves domestically developed H1N1 influenza vaccine (Sinovac Panflu.1 among first)中国批准国产甲型H1N1流感疫苗（科兴Panflu.1等为首批）

2009-09-03public-healthChina/Asia中国/亚洲Immune免疫

In Sep 2009 China became among the first countries to approve a domestically produced influenza A(H1N1) vaccine after the 2009 pandemic declaration, enabling rapid national procurement and deployment.2009年9月，在甲型H1N1大流行宣布后，中国成为最早批准国产甲流疫苗的国家之一，为快速国家采购与部署创造条件。

Why it matters: 为何重要：Demonstrated China’s vaccine industrial surge capacity between SARS and COVID eras.展示中国在SARS与新冠之间疫苗产业的快速扩产能力。

China Daily / Sinovac ↗ · a-2009-h1n1-china

WHO declares influenza A(H1N1) pandemicWHO宣布甲型H1N1流感大流行

2009-06-11public-healthImmune免疫

First influenza pandemic of the 21st century; tested revised IHR and national vaccine surge capacity including China’s rapid domestic approvals.21世纪首次流感大流行；检验修订后IHR与各国疫苗扩产能力，包括中国快速国产获批。

Why it matters: 为何重要：Bridge between SARS lessons and COVID-era pandemic playbooks.连接SARS教训与新冠大流行应对手册的桥梁。

WHO ↗ · a-2009-h1n1-who

CDC MMWR: progress in HepB prevention via universal infant vaccination — China 1997–2006美国CDC《MMWR》：中国1997–2006普遍婴儿乙肝疫苗接种进展

2007-05-11milestoneChina/Asia中国/亚洲Immune免疫

MMWR documented sharp declines in childhood HBsAg prevalence after China integrated HepB into the NIP and ran the China–GAVI project, setting the stage for <1% under-5 carrier goals.《MMWR》记录中国将乙肝纳入国家免疫规划并实施中国–GAVI项目后儿童HBsAg流行率大幅下降，为5岁以下携带率<1%目标奠基。

Why it matters: 为何重要：Quantitative proof that national vaccine policy can bend chronic viral hepatitis epidemiology at population scale.量化证明国家疫苗政策可在人群尺度扭转慢性病毒性肝炎流行病学。

CDC MMWR ↗ · a-2007-hepb-mmwr

China–GAVI hepatitis B immunization: millions of children protected in western/central provinces中国–GAVI乙肝免疫：中西部省份数百万儿童得到保护

2006-07-25public-healthChina/Asia中国/亚洲Immune免疫

By 2006 China and GAVI reported ~11.1 million children immunized against hepatitis B in poorest western/central provinces since 2002 project start; HepB had been added to China’s NIP in 2002 with free EPI vaccines from 2005.至2006年中国与GAVI报告自2002年项目启动以来，中西部最贫困地区约1110万儿童接种乙肝疫苗；乙肝疫苗2002年纳入国家免疫规划，2005年起EPI疫苗免费。

Why it matters: 为何重要：Landmark for reducing chronic HBV and liver-cancer risk in China—one of the century’s great Asia public-health wins.显著降低中国慢性乙肝与肝癌风险的里程碑——本世纪亚洲公卫重大成就之一。

GAVI / China MoH ↗ · a-2006-hepb-china

WHO International Health Regulations (2005) adopted after SARSSARS后WHO通过《国际卫生条例（2005）》

2005-05-23milestoneImmune免疫

World Health Assembly adopted the revised IHR (2005), expanding obligations for detection, assessment, notification and response to public-health emergencies of international concern—directly shaped by SARS experience.世界卫生大会通过修订后的《国际卫生条例（2005）》，扩大对国际关注突发公共卫生事件的监测、评估、通报与应对义务——直接受SARS经验塑造。

Why it matters: 为何重要：Legal backbone of modern global health security still governing Asia outbreak responses.现代全球卫生安全的法律骨架，仍规范亚洲疫情应对。

Institutions: 机构：HKU Med港大医学

WHO ↗ · a-2005-ihr

SARS outbreak contained: China/Asia crisis reshapes global epidemic preparednessSARS暴发得到控制：中国/亚洲危机重塑全球疫情准备

2003-07-05public-healthChina/Asia中国/亚洲Immune免疫

WHO declared the SARS epidemic contained in July 2003 after the 2002–2003 coronavirus outbreak that began in Guangdong and spread via Hong Kong and international travel. Exposed gaps in surveillance, hospital infection control, and cross-border reporting.2002–2003年始于广东、经香港与国际旅行扩散的冠状病毒疫情后，WHO于2003年7月宣布SARS疫情得到控制。暴露监测、医院感染控制与跨境报告短板。

Why it matters: 为何重要：Foundational Asia-centered lesson that later informed IHR revisions and COVID-era responses; slightly predates 2005 window but essential context.以亚洲为中心的奠基性教训，影响后续《国际卫生条例》修订与新冠应对；略早于2005窗口但为必要背景。

Institutions: 机构：HKU Med港大医学 · Queen Mary HK玛丽医院

WHO ↗ · a-2003-sars

Caveats说明与局限